Abstract Library

#3047 Functional Consequence of β-Arrestin 1 Gene Knock-Out in Pancreatic Neuroendocrine Tumor Cell Line BON-1

Introduction: An important limiting factor influencing treatment efficacy of neuroendocrine tumors (NETs) with somatostatin analogs (SSA) is the availability of somatostatin receptors (SSTR) on NETs. While downregulation or altered pattern of SSTR expression are important considerations, receptor internalization/desensitization by β-arrestins may be a crucial contributing factor. Interestingly, our previous study showed a preferential higher expression of β-arrestin 1 (ARRB1), in gastroenteropancreatic NETS (GEP-NETs) compared to pituitary adenomas.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Iyer A

Authors: Iyer A, Vriens J, Dogan-Oruç F, van Koetsveld P, Hofland L,

Keywords: β-arrestin 1, CRISPR-Cas9, BON-1, knock-out, SSTR, SSA, Pan-NET,

#2988 Epigenetic Treatment with Histone Deacetylase Inhibitor Enhances Uptake of [111In]In-DOTA-TATE by Increased SST2 Expression on Neuroendocrine Tumor Cells

Introduction: The somatostatin-2 receptor (SST2) is a target for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NETs). By using epigenetic drugs, which can regulate gene transcription, PRRT efficacy may be further improved due to enhanced SST2 expression.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Klomp I

Authors: Klomp I, Dalm S, van Koetsveld P, Dogan-Oruç F, de Jong M,

Keywords: neuroendocrine tumors, bon-1, epigenetic, histone, histone deacetylase inhibitor, HDACi, upregulation, reversibility, somatostatin receptor-2, somatostatin,

#2905 DNA Methyltransferase Inhibitor Hydralazine Induces Upregulation of Somatostatin Type 2 Receptors in Human Neuroendocrine Tumor Cells

Introduction: Epidrugs like DNA methyltransferase inhibitors (DNMTi) can increase somatostatin receptor type 2 (SST2) expression in neuroendocrine tumor (NET) cells in vitro and in vivo. This effect could be used for NET patients with low SST2 expression who are currently ineligible for somatostatin analogue (SSA) treatment. However, the DNMTi known to stimulate SST2 have either a high toxicity profile or are not yet approved.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Refardt J

Authors: Refardt J, Klomp I, van Koetsveld P, Dogan-Oruç F, de Herder W,

Keywords: somatostatin type 2 receptor, BON-1, GOT-1, upregulation, DNA methyltransferase inhibitor, histone deacetylase inhibitor, epigenetic,

#2271 Effects of Multi-Receptor Targeting Drugs in Neuroendocrine Tumors Using 3D Cell Culture

Introduction: Symptom control in functioning neuroendocrine tumors(NETs) may be difficult in some cases, thus, new therapeutic options, including multi-receptor targeting drugs are required.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Herrera-Martínez A

Authors: Herrera-Martínez A, Van Dungen R, Van Koetsveld P, Dogan-Oruc F, Culler M,

Keywords: NETs, somatostatin receptors, dopamine receptors, multi-receptor targeting drugs, hormone secretion,

#2101 The Effect of Temozolomide on Pancreatic Neuroendocrine Tumors in Vitro and Role of MGMT and MMR System in Temozolomide Resistance

Introduction: Temozolomide (TMZ) has been suggested as a treatment option for patients with pancreatic neuroendocrine tumours (PNETs). The tumour response to TMZ has been linked to expression levels of O6-methylguanine-DNA methyltransferase (MGMT) and components of the mismatch repair (MMR) system.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Blazevic A

Authors: Blazevic A, Dogan-Oruc F, Dedeci M, Van Koetsveld P, Feelders R,

Keywords: Pancreatic neuroendocrine tumors, Temozolomide, Cell lines, Tumor growth, O6-methylguanine-DNA methyltransferase (MGMT), Mismatch repair (MMR) system,